Last reviewed · How we verify
Glassia
At a glance
| Generic name | Glassia |
|---|---|
| Also known as | as alpha-1 antitrypsin, A1PI, alpha-1 proteinase inhibitor, Alpha 1 antitrypsin, Alpha1-Proteinase Inhibitor |
| Sponsor | Octapharma |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency (Phase 1)
- A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks (Phase 1)
- Phase II, Double-Blind, Placebo-Controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects (Phase 2)
- An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysem (Phase 4)
- Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin (N/A)
- Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency (N/A)
- A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fib (Phase 2)
- ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glassia CI brief — competitive landscape report
- Glassia updates RSS · CI watch RSS
- Octapharma portfolio CI